Oncology
14 drugs are in development for Pancreatic Cancer.
- Companies
- 12
- Clinical trials
- 121
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Pancreatic Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
Phase 2(1)
| Drug | Company |
|---|---|
| ngm120 | NGM BIOPHARMACEUTICALS INC (NGM) |
Phase 1(7)
Preclinical(3)
| Drug | Company |
|---|---|
| nano-candesartan | Revium Rx. (RVRC) |
| pancalert | Mainz Biomed N.V. (QUCY) |
| prp | Propanc Biopharma, Inc. (PPCB) |
Phase 1/Phase 2(2)
| Drug | Company |
|---|---|
| IDE892 | IDEAYA Biosciences, Inc. (IDYA) |
| tc-510 | TCR2 THERAPEUTICS INC. (TCRR) |
About this indication
Pancreatic Cancer context
Oncology·MeSH: Pancreatic Neoplasms (D010190)
Narrower concept of MeSH descriptor Pancreatic Neoplasms
Prevalence
8.0 / 100K
Incidence
13.1 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Pancreatic Cancer?
BioSniper tracks 14 drugs in development for Pancreatic Cancer across 12 companies.
How many clinical trials target Pancreatic Cancer?
There are 121 clinical trials targeting Pancreatic Cancer tracked by BioSniper.
What is the prevalence of Pancreatic Cancer?
The estimated prevalence of Pancreatic Cancer is approximately 8.0 per 100,000 population.